Cover Image
市場調查報告書

亞太地區的大腸癌治療藥市場

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

出版商 GBI Research 商品編碼 318827
出版日期 內容資訊 英文 143 Pages
訂單完成後即時交付
價格
Back to Top
亞太地區的大腸癌治療藥市場 Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market
出版日期: 2017年07月01日 內容資訊: 英文 143 Pages
簡介

本報告提供亞太地區各國 的大腸癌 (CRC) 治療藥的市場相關分析,調查疾病概要和主要的治療模式,已上市產品概要(安全性、功效等),現在開發中的治療藥的開發平台資訊,地區整體及主要國家的市場趨勢預測(今後8年的預測值),資本交易、產業聯盟的動向等。

第1章 目錄

第2章 簡介

  • 疾病概要
  • 流行病學
  • 症狀
  • 病因、病理生理學
    • 病因
    • 病理生理學
    • 引人注目的生物標記/標的
  • 診斷
    • 數位式直腸檢驗
    • 大便潛血試驗
    • 彈性S狀結腸鏡檢驗
    • 大腸內視鏡檢驗
    • 虛擬大腸鏡檢查內視鏡檢驗
    • 雙重造影鋇灌腸
  • 分期
  • 預後
  • 治療指南和選擇
    • 外科手術、放射治療
    • 化療
    • 標靶治療
    • 對藥物療法的反抗
    • 治療流程

第3章 已上市產品

  • 概要
  • 化療
    • Lonsurf (Trifluridine plus Tipiracil) - 大鵬藥品工業
    • TS-1 (Tegafur plus Gimeracil plus Oteracil) - 大鵬藥品工業
    • UFT (tegafur plus uracil) - Merck KGaA
  • 表皮成長因素受體 (EGFR) 標靶治療
    • Erbitux (Cetuximab) - Eli Lilly/Merck KGaA
    • Vectibix (panitumumab) - Amgen/武田藥品工業
  • 血管新生阻礙療法
    • Avastin (Bevacizumab) - Roche
    • Cyramza (Ramucirumab) - Eli Lilly
    • Zaltrap (Ziv-Aflibercept) - Sanofi/Regeneron
  • 血管新生阻礙療法
    • Stivarga (Regorafenib) - Bayer/Onyx
  • 已上市產品的功效、安全性比較

第4章 開發平台分析

  • 概要
  • 開發中產品:各開發階段,各分子類型,各投藥途徑,計劃的各類型
  • 開發中產品:各目標分子
  • 開發平台上的有前途的候補藥
    • Keytruda (Pembrolizumab) - Merck & Co.
    • Tecentriq plus Cotellic (Atezolizumab plus cobimetinib) - Roche
    • Napabucasin (BBI-608) - 大日本住友製藥
    • Encorafenib+binimetinib (LGX-818/MEK-162) - Array BioPharma
    • mashichinibu - AB Science
    • Fruquintinib (HMPL-013) - Hutchison MediPharma
    • Famitinib (SHR-1020) - Jiangsu Hengrui Medicine
    • Anlotinib (AL-3818) - Jiangsu Chia-Tai Tianqing
    • Donafenib (CM-4307) - Suzhou Zelgen Biopharmaceuticals
  • 開發中產品的功效、安全性比較
  • 產品競爭力分析的組成架構

第5章 臨床實驗分析

  • 失敗率
    • 整體失敗率
    • 失敗率:各相位、各分子類型
    • 失敗率:各相位、各目標分子
  • 臨床實驗的規模
    • 每1產品的參加患者數:各分子類型,各開發階段
    • 每1產品的參加患者數:各目標分子,各開發階段
    • 每1件臨床實驗的參加患者數:各分子類型,各開發階段
    • 每1件臨床實驗的參加患者數:各目標分子,各開發階段
  • 臨床實驗期間
    • 臨床實驗期間:各分子類型,各開發階段
    • 臨床實驗期間:各目標分子,各開發階段
  • 摘要

第6章 各地區的複數方案預測

  • 概要
  • 亞太地區市場
  • 印度
    • 治療藥的使用模式
    • 年度治療費用
    • 市場規模
  • 中國
  • 澳洲
  • 韓國
  • 日本

第7章 市場促進、阻礙因素

第8章 資本交易及策略性企業整合

  • 授權合約
  • 共同開發契約

第9章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GBIHC448MR

Executive Summary

Colorectal cancer (CRC) originates in either the colon or the rectum. It is one of the most common types of cancers, and is the third most common cancer among men and the second most common in women (ACS, 2017a; Ferlay et al., 2016). CRC is a high-mortality cancer, with mortality rates just behind those of lung, liver, and stomach cancer. It's global age-standardized mortality rates are 20.6 and 14.3 deaths per 100,000 population for men and women, respectively (Ferlay et al., 2016). Most cases of CRC present as adenocarcinomas, but other types of CRC include gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, primary colorectal lymphoma, leiomyosarcoma, melanoma and squamous cell carcinoma (Kim et al., 2016).

China has the most newly diagnosed CRC cases in Asia-Pacific (APAC). In 2011, there were 310,200 incident cases in the country and this rose to 376,300 in 2015. CRC is the most common malignancy among Chinese males, with an estimated incidence of 215,700 men and 160,600 women in 2015. Mortality in 2011 stood at 149,700, and in 2015 rose to 191,000 (Chen et al., 2016).

In Japan, the incidence and mortality of CRC have substantially increased. In 2012, the incidence of colon and rectum cancer in Japan was 87,800 and 46,800 cases respectively, and mortality was 32,200 and 15,100 cases (NCC, 2016a). CRC is a major cause of death in Japan, where it accounts for the largest number of deaths from malignant neoplasms among women, and the third largest among men (Watanabe et al., 2015). In 2016, there were an estimated 147,200 new CRC cases and 51,600 deaths in the country (NCC, 2016b).

In Australia, the five-year survival rate increased from 50% between 1984 and 1988 to 69% between 2009 and 2013. Improvement in survival from CRC may be due to earlier diagnosis and the availability of better treatment options (AGCA, 2017). The incidence of CRC is still several folds lower in India than in most developing and developed countries (Mallath, 2014). However, the country has witnessed a steady increase in numbers in line with its increasing urbanization.

The report "Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" analyzes the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. Furthermore, this report helps to understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.

Companies mentioned in this report: Merck & Co., Roche, Sumitomo Dainippon Pharma, Array BioPharma, AB Science, Hutchison MediPharma, Jiangsu Chia-Tai Tianqing, Suzhou Zelgen Biopharmaceuticals

Scope

The CRC Asia-Pacific market will be valued at $7.9 billion in 2023, growing from $4.7 billion in 2016 at a CAGR of 7.9%.

How will immune checkpoint inhibitors such as Keytruda and Tecentriq contribute to growth?

What effect will patent expirations of currently branded therapies have on market value?

The CRC pipeline is large and diverse, with an strong presence of mAbs and targeted therapies.

What are the common targets and mechanisms of action of pipeline therapies?

Will the pipeline address unmet needs such as the lack of targeted therapies available for BRAF-mutant CRC patients?

What implications will the increased focus on targeted therapies have on the future of CRC treatment?

Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.

How have the late-stage therapies performed in clinical trials?

How would the approval of encorafenib plus binimetinib to treat BRAF-mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.

How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?

How could changes in risk factors such as population age, obesity and lifestyle influence the market?

Licensing deals are the most common form of strategic alliance in CRC, with total deal values ranging from under $10m to over $3 billion.

How do deal frequency and value compare between target families and molecule types?

What were the terms and conditions of key licensing deals?

Reasons to buy

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the CRC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict CRC market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the CRC deals landscape by analyzing trends in licensing and co-development deals.

1 Table of Contents

1 Table of Contents 5

  • 1.1 List of Tables 8
  • 1.2 List of Figures 8

2 Introduction 10

  • 2.1 Disease Introduction 10
  • 2.2 Epidemiology 10
  • 2.3 Symptoms 12
  • 2.4 Etiology and Pathophysiology 12
    • 2.4.1 Etiology 12
    • 2.4.2 Pathophysiology 13
    • 2.4.3 Biomarkers/Targets of Interest 14
  • 2.5 Diagnosis 15
    • 2.5.1 Digital Rectal Examination 16
    • 2.5.2 Fecal Occult Blood Test 16
    • 2.5.3 Flexible Sigmoidoscopy 16
    • 2.5.4 Colonoscopy 16
    • 2.5.5 Virtual Colonoscopy 17
    • 2.5.6 Double Contrast Barium Enema 17
  • 2.6 Disease Stages 17
  • 2.7 Prognosis 19
  • 2.8 Treatment Guidelines and Options 20
    • 2.8.1 Surgery and Radiation Therapy 20
    • 2.8.2 Chemotherapy 21
    • 2.8.3 Targeted Therapies 22
    • 2.8.4 Resistance to Pharmacological Therapies 23
    • 2.8.5 Treatment Algorithm 23

3 Marketed Products 26

  • 3.1 Overview 26
  • 3.2 Chemotherapies 26
    • 3.2.1 Lonsurf (Trifluridine plus Tipiracil) - Taiho Pharma 27
    • 3.2.2 TS-1 (Tegafur plus Gimeracil plus Oteracil) - Taiho Pharma 28
    • 3.2.3 UFT (tegafur plus uracil) - Merck KGaA 29
  • 3.3 Epidermal Growth Factor Receptor Targeted Therapies 29
    • 3.3.1 Erbitux (cetuximab) - Eli Lilly/Merck KGaA 30
    • 3.3.2 Vectibix (panitumumab) - Amgen/Takeda 31
  • 3.4 Anti-angiogenesis Therapies 33
    • 3.4.1 Avastin (bevacizumab) - Roche 33
    • 3.4.2 Cyramza (ramucirumab) - Eli Lilly 35
    • 3.4.3 Zaltrap (Ziv-Aflibercept) - Sanofi/Regeneron 36
  • 3.5 Kinase Inhibitors 37
    • 3.5.1 Stivarga (regorafenib) - Bayer/Onyx 37
  • 3.6 Comparative Efficacy and Safety of Marketed Products 38

4 Pipeline Analysis 40

  • 4.1 Overview 40
  • 4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 40
  • 4.3 Pipeline by Molecular Target 43
  • 4.4 Promising Pipeline Candidates 45
    • 4.4.1 Keytruda (pembrolizumab) - Merck & Co. 45
    • 4.4.2 Tecentriq plus Cotellic (Atezolizumab plus cobimetinib) - Roche 47
    • 4.4.3 Napabucasin (BBI-608) - Sumitomo Dainippon Pharma 49
    • 4.4.4 Encorafenib plus binimetinib (LGX-818/MEK-162) - Array BioPharma 50
    • 4.4.5 Masitinib - AB Science 52
    • 4.4.6 Fruquintinib (HMPL-013) - Hutchison MediPharma 54
    • 4.4.7 Famitinib (SHR-1020) - Jiangsu Hengrui Medicine 55
    • 4.4.8 Anlotinib (AL-3818) - Jiangsu Chia-Tai Tianqing 56
    • 4.4.9 Donafenib (CM-4307) - Suzhou Zelgen Biopharmaceuticals 57
  • 4.5 Comparative Efficacy and Safety of Pipeline Products 58
  • 4.6 Product Competitiveness Framework 59

5 Clinical Trial Analysis 61

  • 5.1 Failure Rate 61
    • 5.1.1 Overall Failure Rate 61
    • 5.1.2 Failure Rate by Phase and Molecule Type 62
    • 5.1.3 Failure Rate by Phase and Molecular Target 63
  • 5.2 Clinical Trial Size 64
    • 5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development 64
    • 5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development 65
    • 5.2.3 Patient Enrollment per Trial by Molecule Type and Stage of Development 66
    • 5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development 67
  • 5.3 Clinical Trial Duration 68
    • 5.3.1 Trial Duration by Molecule Type and Stage of Development 68
    • 5.3.2 Trial Duration by Molecular Target and Stage of Development 69
  • 5.4 Summary of Clinical Trial Metrics 70

6 Multi-scenario Forecast 72

  • 6.1 Overview 72
  • 6.2 Asia-Pacific Market 72
  • 6.3 India 74
    • 6.3.1 Treatment Usage Patterns 74
    • 6.3.2 Annual Cost of Therapy 75
    • 6.3.3 Market Size 77
  • 6.4 China 78
    • 6.4.1 Treatment Usage Patterns 78
    • 6.4.2 Annual Cost of Therapy 79
    • 6.4.3 Market Size 80
  • 6.5 Australia 81
    • 6.5.1 Treatment Usage Patterns 81
    • 6.5.2 Annual Cost of Therapy 81
    • 6.5.3 Market Size 82
  • 6.6 South Korea 83
    • 6.6.1 Treatment Usage Patterns 83
    • 6.6.2 Annual Cost of Therapy 84
    • 6.6.3 Market Size 86
  • 6.7 Japan 87
    • 6.7.1 Treatment Usage Patterns 87
    • 6.7.2 Annual Cost of Therapy 88
    • 6.7.3 Market Size 89

7 Drivers and Barriers 90

  • 7.1 Drivers 90
    • 7.1.1 Increasing Elderly Population and Incidence of CRC 90
    • 7.1.2 Increasing Screening Programs and Approval of New Screening Tests for CRC to Drive Early Diagnosis Rate 90
    • 7.1.3 Increase in Mutation Testing to Drive Market Growth 90
    • 7.1.4 Availability of Novel First-, Second- and third-Line Therapy Options in Pipeline 90
    • 7.1.5 Diversified Healthcare Reform to Boost Market Growth 91
    • 7.1.6 Diversified Health Insurance System to Help Nurture Growth 91
  • 7.2 Barriers 92
    • 7.2.1 Patent Expiration of Branded Therapies to Affect CRC Market Growth 92
    • 7.2.2 High Prices of Therapeutics to Slow Down Market Growth 92
    • 7.2.3 Limited Incorporation of Immunotherapies in the CRC Treatment Algorithm 92
    • 7.2.4 Lack of Development of Neoadjuvant and Adjuvant Pipeline Products 92
    • 7.2.5 Lack of Reimbursement and Penetration of Generic Drugs to Hinder Market Growth in China and India 93
    • 7.2.6 Drug Pricing Reforms 93

8 Deals and Strategic Consolidations 94

  • 8.1 Licensing Deals 94
    • 8.1.1 Deals by Region and Value 94
    • 8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 95
    • 8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 96
    • 8.1.4 Key Licensing Deals 99
  • 8.2 Co-development Deals 101
    • 8.2.1 Deals by Region and Value 101
    • 8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 102
    • 8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 103
    • 8.2.4 Key Co-development Deals 106

9 Appendix 108

  • 9.1 All Pipeline Drugs by Stage of Development 108
    • 9.1.1 Discovery 108
    • 9.1.2 Preclinical 110
    • 9.1.3 Investigational New Drug/Clinical Trial Authorization-Filed 115
    • 9.1.4 Phase I 115
    • 9.1.5 Phase II 119
    • 9.1.6 Phase III 123
    • 9.1.7 Pre-registration 123
  • 9.2 Summary of Multi-scenario Market Forecasts to 2023 124
    • 9.2.1 Asia-Pacific 124
    • 9.2.2 India 124
    • 9.2.3 China 124
    • 9.2.4 Australia 125
    • 9.2.5 South Korea 125
    • 9.2.6 Japan 125
  • 9.3 Bibliography 126
  • 9.4 Abbreviations 136
  • 9.5 Research Methodology 139
    • 9.5.1 Secondary Research 140
    • 9.5.2 Marketed Product Profiles 140
    • 9.5.3 Late-Stage Pipeline Candidates 140
    • 9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 140
    • 9.5.5 Product Competitiveness Framework 141
    • 9.5.6 Pipeline Analysis 141
    • 9.5.7 Forecasting Model 142
    • 9.5.8 Deals Data Analysis 143
  • 9.6 Contact Us 143
  • 9.7 Disclaimer 143

1.1 List of Tables

  • Table 1: CRC Therapeutics Market, Symptoms of CRC 12
  • Table 2: CRC Therapeutics Market, Stage Definitions for CRC 18
  • Table 3: CRC Therapeutics Market, Prognosis for CRC 20
  • Table 4 CRC Therapeutics, Surgical Options for CRC 20
  • Table 5: CRC Therapeutics Market, Global, Licensing Deals Valued $10m and Above, 2006-2017 101
  • Table 6: CRC Therapeutics Market, Global, Co-development Deals Value, 2006-2016 107
  • Table 7: CRC Therapeutics Market, Global, All Pipeline Products, Discovery, 2017 108
  • Table 8: CRC Therapeutics Market, Global, All Pipeline Products, Preclinical, 2017 110
  • Table 9: CRC Therapeutics Market, Global, All Pipeline Products, IND/CTA-Filed, 2017 115
  • Table 10: CRC Therapeutics Market, Global, All Pipeline Products, Phase I, 2017 115
  • Table 11: CRC Therapeutics Market, Global, All Pipeline Products, Phase II, 2017 119
  • Table 12: CRC Therapeutics Market, Global, All Pipeline Products, Phase III, 2017 123
  • Table 13: CRC Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2017 123
  • Table 14: CRC Therapeutics Market, APAC, Market Forecast, 2016-2023 124
  • Table 15: CRC Therapeutics Market, India, Market Forecast, 2016-2023 124
  • Table 16: CRC Therapeutics Market, China, Market Forecast, 2016-2023 124
  • Table 17: CRC Therapeutics Market, Australia, Market Forecast, 2016-2023 125
  • Table 18: CRC Therapeutics Market, South Korea, Market Forecast, 2016-2023 125
  • Table 19: CRC Therapeutics Market, Japan, Market Forecast, 2016-2023 125

1.2 List of Figures

  • Figure 1: CRC Therapeutics Market, Australia, Age-Specific Incidence and Mortality Rate (per 100,000) in 2013 11
  • Figure 2: CRC Therapeutics, Treatment Algorithm for mCRC 24
  • Figure 3: CRC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products 39
  • Figure 4: CRC Therapeutics Market, Global, Pipeline, 2017 42
  • Figure 5: CRC Therapeutics Market, Global, Pipeline by Molecular Target, 2017 44
  • Figure 6: CRC Therapeutics Market, Pipeline by Molecular Target and Stage of Development, 2017 45
  • Figure 7: CRC Therapeutics Market, APAC, Keytruda Forecast ($m), 2021-2023 47
  • Figure 8: CRC Therapeutics Market, APAC, Tecentriq plus Cotellic Forecast ($m), 2021-2023 48
  • Figure 9: CRC Therapeutics Market, APAC, Napabucasin Forecast ($m), 2021-2023 50
  • Figure 10: CRC Therapeutics Market, APAC, Encorafenib plus Binimetinib Forecast ($m), 2021-2023 52
  • Figure 11: CRC Therapeutics Market, APAC, Masitinib Forecast ($m), 2019-2023 53
  • Figure 12: CRC Therapeutics Market, APAC, Fruquintinib Forecast ($m), 2018-2023 55
  • Figure 13: CRC Therapeutics Market, APAC, Famitinib Forecast ($m), 2019-2023 56
  • Figure 14: CRC Therapeutics Market, APAC, Anlotinib Forecast ($m), 2020-2023 57
  • Figure 15: CRC Therapeutics Market, APAC, Donafenib Forecast ($m), 2021-2023 58
  • Figure 16: CRC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products 58
  • Figure 17: CRC Therapeutics Market, Competitor Matrix for CRC Marketed and Pipeline First-Line Products, 2017 60
  • Figure 18: CRC Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006-2016 62
  • Figure 19: CRC Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006-2016 63
  • Figure 20: CRC Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006-2016 64
  • Figure 21: CRC Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006-2016 65
  • Figure 22: CRC Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2006-2016 66
  • Figure 23: CRC Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2006-2016 67
  • Figure 24: CRC Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2006-2016 68
  • Figure 25: CRC Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2006-2016 69
  • Figure 26: CRC Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2006-2016 70
  • Figure 27: CRC Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 71
  • Figure 28: CRC Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 71
  • Figure 29: CRC Therapeutics Market, APAC, Treatment Patterns ('000), 2016-2023 73
  • Figure 30: CRC Therapeutics Market, APAC, Market Size ($bn), 2016-2023 74
  • Figure 31: CRC Therapeutics Market, India, Treatment Patterns ('000), 2016-2023 75
  • Figure 32: CRC Therapeutics Market, India, Annual Cost of Therapy ($), 2016-2023 76
  • Figure 33: CRC Therapeutics Market, India, Market Size ($m), 2016-2023 77
  • Figure 34: CRC Therapeutics Market, China, Treatment Patterns ('000), 2016-2023 78
  • Figure 35: CRC Therapeutics Market, China, Annual Cost of Therapy ($), 2016-2023 79
  • Figure 36: CRC Therapeutics Market, China, Market Size ($bn), 2016-2023 80
  • Figure 37: CRC Therapeutics Market, Australia, Treatment Patterns ('000), 2016-2023 81
  • Figure 38: CRC Therapeutics Market, Australia, Annual Cost of Therapy ($), 2016-2023 82
  • Figure 39: CRC Therapeutics Market, Australia, Market Size ($m), 2016-2023 83
  • Figure 40: CRC Therapeutics Market, South Korea, Treatment Patterns ('000), 2016-2023 84
  • Figure 41: CRC Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2016-2023 85
  • Figure 42: CRC Therapeutics Market, South Korea, Market Size ($m), 2016-2023 86
  • Figure 43: CRC Therapeutics Market, Japan, Treatment Patterns ('000), 2016-2023 87
  • Figure 44: CRC Therapeutics Market, Japan, Annual Cost of Therapy ($), 2016-2023 88
  • Figure 45: CRC Therapeutics Market, Japan, Market Size ($bn), 2016-2023 89
  • Figure 46: CRC Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2017 95
  • Figure 47: CRC Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2017 96
  • Figure 48: CRC Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017 97
  • Figure 49: CRC Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2017 98
  • Figure 50: CRC Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006-2017 99
  • Figure 51: CRC Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2006-2017 102
  • Figure 52: CRC Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2017 103
  • Figure 53: CRC Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017 104
  • Figure 54: CRC Therapeutics Market, Global, Co-development Deals by Molecule type and Stage of Development, 2006-2016 105
  • Figure 55: CRC Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006-2016 106
Back to Top